NCT06749379

Brief Summary

Lipedema is a chronic debilitating condition that impacts the subcutaneous adipose tissue of the extremities. It is a chronic condition but should not be regarded as always progressing.The clinical course varies individually and is unpredictable. It may considerably diminish the patient's quality of life. Fibromyalgia, similar to lipedema, is a debilitating chronic pain disease of unclear origin that primarily affects women. It is a complex syndrome marked by widespread pain and tenderness. Fibromyalgia and lipedema are both marked by pain related to soft tissue. Both disorders are not amenable to curative treatment, resulting in a significant burden on individual and public health. No definitive indicators, including abnormal laboratory or imaging results, can be discerned to differentiate one disorder from another. With this perspective, the aim of our study was to evaluate the presence of lipedema and lipedema-related factors in fibromyalgia patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2023

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

December 19, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 27, 2024

Completed
Last Updated

December 27, 2024

Status Verified

December 1, 2024

Enrollment Period

7 months

First QC Date

December 19, 2024

Last Update Submit

December 19, 2024

Conditions

Keywords

fibromyalgia, lipedema, awareness

Outcome Measures

Primary Outcomes (5)

  • visual analog scale

    Patients were asked to mark the severity of their widespread body pain in the last week on a 10 cm visual analog scale (VAS) (0: no pain, 10: unbearable pain, the higher the measured value, the greater the pain intensity).

    1 month

  • Presence and stages of lipedema were diagnosed according to S1 guidelines of the German Society of Phlebology

    Overview of diagnostic criteria for lipedema; Initiation during puberty, pregnancy, or menopause, characterized by disproportionate proliferation of adipose tissue (extremities, trunk), cuffing around the joints, unaffected hands and feet, sensations of heaviness and tightness in the affected extremities, tenderness upon palpation or spontaneous pain - escalating throughout the day, edema - worsening over the course of the day, easy bruising, and a negative Stemmer's sign. Lipedema stage characteristics: stage 1: Smooth skin with a uniform increase in subcutaneous tissue; stage 2: Irregular skin surface with indentations and nodular alterations in the subcutaneous tissue; stage 3: Significant increase in circumference accompanied by loose skin/tissue ('dewlap').

    1 month

  • The American College of Rheumatology (ACR) 2016 Fibromyalgia Diagnostic Criteria

    It is a compilation of diagnostic criteria formulated for the identification of fibromyalgia, established following the modification of previously utilized diagnostic criteria. It comprises two components: the widespread pain index (WPI) and the symptom severity scale (SSS). The assessment of the WPI involves indicating persistent pain over the past seven days across five anatomical regions (upper left, upper right, lower left, lower right, axial) and 19 specific body areas (both jaws, shoulders, upper arms, lower arms, hips, upper legs, lower legs, neck, upper back, lower back, chest, and abdomen). Each region is assigned one point. The cumulative score varies from 0 to 19. For a diagnosis of widespread pain, pain must be evident in a minimum of 4 out of 5 anatomical regions.

    1 month

  • The Revised Fibromyalgia Impact Questionnaire

    It is a questionnaire designed to assess functional limitations and disabilities resulting from fibromyalgia. The questionnaire comprises a total of 21 questions divided into three sections: function, overall impact, and symptoms. Responses to each inquiry are indicated on a scale ranging from 0 to 10. The overall score is determined by summing the results: the score of the first section is divided by three, the score of the second section by one, and the score of the third section by two. Elevated scores signify a greater fibromyalgia-associated impairment

    1 month

  • Beck Depression Inventory

    It is a scale designed to assess the intensity and severity of depression symptoms. The scale comprises 21 items utilizing a 4-point Likert format, with each item rated from 0 to 3. Higher scores indicate more severe depressive symptoms

    1 month

Interventions

Lipedema stage characteristics: stage 1: Smooth skin with a uniform increase in subcutaneous tissue; stage 2: Irregular skin surface with indentations and nodular alterations in the subcutaneous tissue; stage 3: Significant increase in circumference accompanied by loose skin/tissue ('dewlap').

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study included 100 female patients over the age of 18 who met the fibromyalgia diagnostic criteria according to the American College of Rheumatology (ACR) 2016 Fibromyalgia Diagnostic Criteria.

You may qualify if:

  • female patients
  • over the age of 18
  • who met the fibromyalgia diagnostic criteria according to the American College of Rheumatology (ACR) 2016 Fibromyalgia Diagnostic Criteria

You may not qualify if:

  • renal or cardiac insufficiency,
  • the use of any drug that could influence body fluid and electrolyte balance,
  • the presence of a major somatic disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ufuk University

Ankara, 06510, Turkey (Türkiye)

Location

MeSH Terms

Conditions

FibromyalgiaLipedema

Interventions

Restraint, Physical

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesConnective Tissue DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Behavior ControlTherapeuticsImmobilizationInvestigative Techniques

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

December 19, 2024

First Posted

December 27, 2024

Study Start

August 1, 2022

Primary Completion

March 1, 2023

Study Completion

March 1, 2023

Last Updated

December 27, 2024

Record last verified: 2024-12

Locations